Literature DB >> 15613934

The potential of minocycline for neuroprotection in human neurologic disease.

Daniel Zemke1, Arshad Majid.   

Abstract

Minocycline is a member of the tetracycline class of molecules with broad-spectrum antibiotic activity. The unique properties of minocycline result in increased tissue distribution when compared with the other tetracyclines. Of particular interest is the ability of minocycline to diffuse into the central nervous system at clinically effective levels. Aside from its antimicrobial properties, minocycline has been found to have beneficial effects on inflammation, microglial activation, matrix metalloproteinases, nitric oxide production, and apoptotic cell death. Concordantly, minocycline has been found to have neuroprotective effects in animal models of a number of diseases including stroke, multiple sclerosis, and Parkinson disease. The proven safety of minocycline over decades of use as an antibiotic suggests that it may have potential for development into an effective treatment of multiple neurologic conditions in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15613934     DOI: 10.1097/01.wnf.0000150867.98887.3e

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  45 in total

Review 1.  Translational approaches to treatment-induced symptoms in cancer patients.

Authors:  Robert Dantzer; Mary W Meagher; Charles S Cleeland
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

Review 2.  Microglia and the control of autoreactive T cell responses.

Authors:  Benoit Melchior; Shweta S Puntambekar; Monica J Carson
Journal:  Neurochem Int       Date:  2006-06-08       Impact factor: 3.921

3.  Profile of minocycline neuroprotection in bilirubin-induced auditory system dysfunction.

Authors:  Ann C Rice; Victoria L Chiou; Sarah B Zuckoff; Steven M Shapiro
Journal:  Brain Res       Date:  2010-11-12       Impact factor: 3.252

4.  Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study.

Authors:  Catherine A Cukras; Philip Petrou; Emily Y Chew; Catherine B Meyerle; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-22       Impact factor: 4.799

Review 5.  Microglia Activation and Schizophrenia: Lessons From the Effects of Minocycline on Postnatal Neurogenesis, Neuronal Survival and Synaptic Pruning.

Authors:  Dragos Inta; Undine E Lang; Stefan Borgwardt; Andreas Meyer-Lindenberg; Peter Gass
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

6.  Differential effects of early postinjury treatment with neuroprotective drugs in a mouse model using diffuse reflectance spectroscopy.

Authors:  Ariel Shochat; David Abookasis
Journal:  Neurophotonics       Date:  2015-01-22       Impact factor: 3.593

7.  Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS.

Authors:  Eva-Maria Ratai; Jeffrey P Bombardier; Chan-Gyu Joo; Lakshmanan Annamalai; Tricia H Burdo; Jennifer Campbell; Robert Fell; Reza Hakimelahi; Julian He; Patrick Autissier; Margaret R Lentz; Elkan F Halpern; Eliezer Masliah; Kenneth C Williams; Susan V Westmoreland; R Gilberto González
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

8.  Role of Spinal Microglia in Visceral Hyperalgesia and NK1R Up-Regulation in a Rat Model of Chronic Stress (Gastroenterology 2009;136:1339-1348).

Authors:  Su Jin Hong
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

Review 9.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.

Authors:  Noriyuki Matsukawa; Takao Yasuhara; Koichi Hara; Lin Xu; Mina Maki; Guolong Yu; Yuji Kaneko; Kosei Ojika; David C Hess; Cesar V Borlongan
Journal:  BMC Neurosci       Date:  2009-10-06       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.